Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr 15;384(15):1468-1470.
doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Kai Wu  1 , Anne P Werner  2 , Matthew Koch  1 , Angela Choi  1 , Elisabeth Narayanan  1 , Guillaume B E Stewart-Jones  1 , Tonya Colpitts  1 , Hamilton Bennett  1 , Seyhan Boyoglu-Barnum  2 , Wei Shi  2 , Juan I Moliva  2 , Nancy J Sullivan  2 , Barney S Graham  2 , Andrea Carfi  1 , Kizzmekia S Corbett  2 , Robert A Seder  2 , Darin K Edwards  3
Affiliations
Clinical Trial

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Kai Wu et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralization of SARS-CoV-2 Pseudoviruses in Serum Samples.
Serum samples obtained from participants who received the mRNA-1273 vaccine in a phase 1 trial were collected on day 36 (7 days after the participants received the second dose of the vaccine). Neutralization was measured with the use of a recombinant vesicular stomatitis virus (rVSV)–based pseudovirus neutralization assay that incorporated D614G or the indicated spike mutations present in the B.1.1.7 variant (Panels A and B), the B.1.351 variant (Panels C and D), or the P.1 variant, the B.1.427/B.1.429 (versions 1 and 2) variants, and the B.1.1.7+E484K variant (Panels E through I). The red dots indicate the results from serum samples of the individual participants; the white dots, white diamonds, and white triangles the same samples tested against the variants shown on the x axis; and the horizontal dashed lines the lower limit of quantification. The reciprocal neutralizing titers on the pseudovirus neutralization assay at a 50% inhibitory dilution (ID50) are shown. In Panels A, C, and E, boxes and horizontal bars denote the interquartile range (IQR) and the median neutralizing titer, respectively. Whisker end points are equal to the maximum and minimum values below or above the median at 1.5 times the IQR. In Panels B, D, F, G, H, and I, the lines connect the D614G and variant neutralization titers in matched samples. We detected reductions by a factor of 1.2 in titers of neutralizing antibodies against the B.1.1.7 variant (Panel B), a factor of 6.4 against the B.1.351 variant (Panel D), a factor of 3.5 against the P.1 variant (Panel F), a factor of 2.3 against the B.1.427/B.1.429-v1 variant (Panel G), a factor of 2.8 against the B.1.427/B.1.429-v2 variant (Panel H), and a factor of 3.1 against the B.1.1.7+E484K variant (Panel I). Statistical analysis of matched pairs was performed with the use of the Wilcoxon signed-rank test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med 2020;383:1920-1931. - PMC - PubMed
    1. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020;383:2427-2438. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416. - PMC - PubMed